Endurant Capital Management’s Quest Diagnostics DGX Stock Holding History

Endurant Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-29,041	Closed	-$3.33M	–	61
2020 Q3	$3.33M	Buy	+29,041	New	+$3.43M	0.98%	35
2018 Q4	–	Sell	-19,673	Closed	-$2.12M	–	57
2018 Q3	$2.12M	Buy	+19,673	New	+$2.16M	0.94%	31
2018 Q2	–	Sell	-13,000	Closed	-$1.3M	–	69
2018 Q1	$1.3M	Buy	+13,000	New	+$1.33M	0.49%	50
2015 Q1	–	Sell	-83,000	Closed	-$5.57M	–	98
2014 Q4	$5.57M	Buy	+83,000	New	+$5.24M	2.18%	15

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Endurant Capital Management's DGX Position: Q4 2020 in Review

Endurant Capital Management sold out of Quest Diagnostics (DGX) in Q4 2020, closing a stake of 29,041 shares — an estimated $3.33M sold.

Endurant Capital Management first reported a position in DGX in Q4 2014 and held it in 4 quarters. The position peaked at $5.57M in Q4 2014. 812 funds tracked by Wall St. Rank hold DGX as of Q4 2020.

Endurant Capital Management reported no remaining Quest Diagnostics position as of Q4 2020 after selling out during the quarter.
Endurant Capital Management sold 29,041 Quest Diagnostics shares in Q4 2020, an estimated $3.33M.
Endurant Capital Management first reported a position in Quest Diagnostics in Q4 2014 and held it in 4 quarters.
Endurant Capital Management's Quest Diagnostics position peaked at $5.57M in Q4 2014.
812 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.